“…Using a number of toolkit inhibitors of GSK-3β, translational studies credentialed GSK-3β as a therapeutic target in multiple tumor types including pancreatic cancer (8, 9), chronic lymphocytic leukemia (10), colon (11), renal (12) and bladder (13) cancer. More recent studies have also shown that the inhibition of GSK-3β suppressed cancer cell viability in models of glioblastoma (14–16), leukemia (17–20), neuroblastoma (21, 22), osteosarcoma (23), melanoma (24), ovarian (25, 26), thyroid (27), prostate (28–30), breast (31–33) and lung cancer (34, 35). Thus, GSK-3β has emerged as a viable therapeutic target for the treatment of a broad spectrum of different cancer types.…”